Ken Griffin Citadel Advisors
Ken Griffin founded Citadel, one of the world’s largest and most successful hedge funds. Starting his trading career from his Harvard dorm room at a young age, Griffin quickly developed a keen sense for markets and built Citadel into a global powerhouse with billions in assets under management. Known for his quantitative and technology-driven strategies, Griffin has also made headlines for significant philanthropic contributions, supporting causes in education, the arts, and public institutions. Over the years, he has earned recognition as one of the preeminent figures in modern finance.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$1.68B |
| 2 |
Synchrony
SYF
|
+$441M |
| 3 |
Meta Platforms (Facebook)
META
|
+$370M |
| 4 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$349M |
| 5 |
Comcast
CMCSA
|
+$338M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AET
Aetna Inc
AET
|
+$783M |
| 2 |
Morgan Stanley
MS
|
+$518M |
| 3 |
Lowe's Companies
LOW
|
+$474M |
| 4 |
Visa
V
|
+$425M |
| 5 |
Netflix
NFLX
|
+$419M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 5.01% |
| 2 | Technology | 4.76% |
| 3 | Consumer Discretionary | 3.82% |
| 4 | Industrials | 3.81% |
| 5 | Communication Services | 3.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
BPMC
5876
PUT
DELISTED
Blueprint Medicines
BPMC
| $631K | ﹤0.01% |
11,700
-7,500
| -39% | -$456K |
|
5877
CALL
Myriad Genetics
MYGN
$290M
| $631K | ﹤0.01% |
21,700
+2,400
| +12% | +$86.3K |
|
5878
ProShares Ultra Health Care
RXL
$89.6M
| $631K | ﹤0.01% |
+27,760
| New | +$713K |
|
|
PRAH
5879
DELISTED
PRA Health Sciences, Inc.
PRAH
| $631K | ﹤0.01% |
6,854
-144,435
| -95% | -$14.6M |
|
5880
PUT
FIVE9
FIVN
$2.47B
| $630K | ﹤0.01% |
14,400
-15,900
| -52% | -$640K |
|
5881
CALL
MannKind Corp
MNKD
$1.24B
| $630K | ﹤0.01% |
594,800
+119,400
| +25% | +$203K |
|
|
HEWY
5882
DELISTED
iShares Currency Hedged MSCI South Korea ETF
HEWY
| $630K | ﹤0.01% |
+26,126
| New | +$678K |
|
5883
NBT Bancorp
NBTB
$2.78B
| $629K | ﹤0.01% |
18,178
-39,637
| -69% | -$1.46M |
|
5884
PUT
Gladstone Capital
GLAD
$446M
| $628K | ﹤0.01% |
+43,000
| New | +$756K |
|
5885
CALL
KNOT Offshore Partners
KNOP
$369M
| $628K | ﹤0.01% |
35,000
+20,900
| +148% | +$422K |
|
5886
PUT
Loews
L
$23.1B
| $628K | ﹤0.01% |
13,800
+5,800
| +73% | +$273K |
|
|
HIBB
5887
PUT
DELISTED
Hibbett, Inc. Common Stock
HIBB
| $628K | ﹤0.01% |
43,900
+29,500
| +205% | +$501K |
|
|
AIV
5888
PUT
Aimco
AIV
$383M
| $627K | ﹤0.01% |
+107,347
| New | +$638K |
|
5889
CALL
Enovis
ENOV
$1.5B
| $627K | ﹤0.01% |
17,430
+8,076
| +86% | +$377K |
|
5890
CALL
Qiagen
QGEN
$8.87B
| $627K | ﹤0.01% |
17,164
+755
| +5% | +$28K |
|
|
SRNE
5891
DELISTED
Sorrento Therapeutics, Inc.
SRNE
| $627K | ﹤0.01% |
261,075
+247,468
| +1,819% | +$808K |
|
|
ARRY
5892
PUT
DELISTED
Array Biopharma Inc
ARRY
| $627K | ﹤0.01% |
44,000
-31,600
| -42% | -$479K |
|
5893
CALL
Lindsay Corp
LNN
$1.17B
| $626K | ﹤0.01% |
6,500
+2,900
| +81% | +$283K |
|
5894
CALL
Ultragenyx Pharmaceutical
RARE
$2.61B
| $626K | ﹤0.01% |
14,400
-24,100
| -63% | -$1.32M |
|
|
EQGP
5895
PUT
DELISTED
EQGP Holdings, LP
EQGP
| $626K | ﹤0.01% |
31,400
+20,700
| +193% | +$383K |
|
5896
Minerva Neurosciences
NERV
$219M
| $625K | ﹤0.01% |
11,580
+1,495
| +15% | +$109K |
|
|
VER
5897
CALL
DELISTED
VEREIT, Inc.
VER
| $625K | ﹤0.01% |
17,480
+10,780
| +161% | +$400K |
|
5898
PUT
Leggett & Platt
LEG
$1.32B
| $624K | ﹤0.01% |
17,400
-4,800
| -22% | -$183K |
|
5899
CALL
ITT
ITT
$19.6B
| $623K | ﹤0.01% |
12,900
+1,700
| +15% | +$89.8K |
|
5900
Regional Management Corp
RM
$309M
| $623K | ﹤0.01% |
25,916
-9,302
| -26% | -$252K |
|
Similar funds
Ken Griffin's Q4 2018 Portfolio in Review
As of Q4 2018, Ken Griffin held 10,385 positions worth $183B, down 19% from $224B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Ken Griffin withdrew a net $8B in Q4 2018, closing 1,371 positions and reducing 3,800 holdings. Its most notable exit was Aetna Inc, an estimated $783M position sold in full.
By sector, the portfolio is most concentrated in Financials at 5% of assets, down from 5.9% a quarter earlier, followed by Technology and Consumer Discretionary.
Against the trend, Ken Griffin opened a new position in Assurant worth $99.4M.
- Ken Griffin's largest Q4 2018 buy was Assurant: 1,111,342 shares worth $99.4M.
- Ken Griffin added most to Amazon in Q4 2018, an estimated $1.68B increase.
- Ken Griffin's biggest Q4 2018 reduction was Morgan Stanley, cutting an estimated $518M.
- Ken Griffin fully exited Aetna Inc in Q4 2018, selling an estimated $783M.
- Ken Griffin's ten largest holdings make up 24% of its $183B portfolio in Q4 2018.
- Ken Griffin opened 1,236 new positions and closed 1,371 in Q4 2018.
- Ken Griffin's portfolio value fell 19% quarter-over-quarter to $183B.
Based on Citadel Advisors's 13F filing for Q4 2018, filed 14 Feb 2019.